QQ客服 官方微博 反馈留言

	A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
	Chen, Jiaying; Ji, Qinghai; Cao, Junning; Ji, Dongmei; Bai, Chunmei; Lin, Yansong; Pan, Bin; Sun, Guofang; Li, Jing; Qi, Chuan
	2017
卷号	35
ISSN号	0732-183X
DOI	10.1200/JCO.2017.35.15_suppl.6037
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6369337
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Chen, Jiaying,Ji, Qinghai,Cao, Junning,et al. A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).[J],2017,35.
APA	Chen, Jiaying.,Ji, Qinghai.,Cao, Junning.,Ji, Dongmei.,Bai, Chunmei.,...&Hua, Ye.(2017).A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC)..,35.
MLA	Chen, Jiaying,et al."A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).".35(2017).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。